Anticoagulation for Stroke Prevention

Anticoagulation is essential for preventing cardioembolic stroke and recurrent thrombosis in specific high-risk conditions. Unlike antiplatelet therapy (which targets arterial atherothrombosis), anticoagulants are indicated when the stroke mechanism involves cardiac embolism, venous thrombosis, or hypercoagulable states. Selecting the right anticoagulant—and knowing when not to use DOACs—is critical.

Indications for Anticoagulation in Stroke Prevention

Indication Preferred Agent Key Evidence
Atrial Fibrillation DOACs preferred over warfarin RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48
Mechanical Heart Valves Warfarin ONLY (DOACs contraindicated) RE-ALIGN (dabigatran caused harm)
Antiphospholipid Syndrome Warfarin preferred (DOACs inferior) TRAPS, ASTRO-APS/TAPS
Cervical Artery Dissection Antiplatelet OR anticoagulation (no difference) CADISS, TREAT-CAD
Cerebral Venous Thrombosis DOACs appear equivalent to warfarin RE-SPECT CVT, ACTION-CVT
LV Thrombus / Intracardiac Thrombus Warfarin traditional; DOACs increasingly used Observational data; RCTs ongoing
PFO with High-Risk Features PFO closure > anticoagulation > antiplatelets CLOSE, RESPECT, REDUCE, DEFENSE-PFO
Rheumatic Mitral Stenosis Warfarin (DOACs not validated) Expert consensus; excluded from DOAC trials

Atrial Fibrillation

Atrial fibrillation (AF) is the most common indication for anticoagulation in stroke prevention. Left atrial stasis leads to thrombus formation (typically in the left atrial appendage), which can embolize to the brain. The annual stroke risk in AF ranges from 1–15% depending on CHA₂DS₂-VASc score.

DOACs vs Warfarin: The Landmark Trials

Four pivotal trials established DOACs as the preferred agents for stroke prevention in non-valvular AF:

RE-LY (2009) — Dabigatran 150mg BID reduced stroke/SE by 34% vs warfarin with similar major bleeding; 110mg BID was non-inferior with less bleeding.

ROCKET-AF (2011) — Rivaroxaban 20mg daily was non-inferior to warfarin for stroke/SE, with similar major bleeding but less intracranial hemorrhage.

ARISTOTLE (2011) — Apixaban 5mg BID reduced stroke/SE by 21%, major bleeding by 31%, and mortality by 11% vs warfarin—the only DOAC to show mortality benefit.

ENGAGE AF-TIMI 48 (2013) — Edoxaban 60mg daily was non-inferior to warfarin with significantly less bleeding and cardiovascular death.

⚡ Clinical Pearl: DOAC Advantages in AF

DOACs offer ~50% reduction in intracranial hemorrhage compared to warfarin across all trials. This ICH reduction is the primary safety advantage, making DOACs preferred unless specifically contraindicated.

Timing of Anticoagulation After AF-Related Stroke

The traditional concern about early anticoagulation was hemorrhagic transformation of the infarct. Four randomized trials and a pooled meta-analysis have now established the safety of early DOAC initiation.

TIMING (2022) — 888 patients randomized to early (≤4 days) vs delayed (5–10 days) DOAC. Primary composite at 90 days: 2.9% early vs 4.1% delayed. Symptomatic ICH 0.2% vs 0.4%. Demonstrated non-inferiority of early initiation.

ELAN (2023) — 2,013 patients randomized to early vs late DOAC based on infarct size (early = ≤48h for minor/moderate, days 6–7 for major). Primary composite at 30 days: 2.9% early vs 4.1% late. Symptomatic ICH 0.2% in both groups. Trend favoring early initiation, with lower recurrent ischemic stroke (1.4% vs 2.5%).

OPTIMAS (2024) — 3,621 patients randomized to early (≤4 days) vs delayed (7–14 days) DOAC. Primary outcome at 90 days: 3.3% in both groups. Symptomatic ICH 0.6% vs 0.7%. Confirms safety of early anticoagulation across all stroke severities.

START (2025) — 200 patients randomized to DOAC initiation at day 3–4, day 6, day 10, or day 14. Day 3–4 group had no ischemic events and highest probability of being optimal. Supports earlier initiation within the first week.

CATALYST Meta-Analysis (2025) — Pooled individual patient data from TIMING, ELAN, OPTIMAS, and START (>6,500 patients). Early DOAC initiation (≤4 days) reduced the composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke at 30 days compared to delayed initiation.

🔹 Practical Timing Guidance

  • TIA / Minor stroke (NIHSS <8, small infarct): Start DOAC within 24–48 hours
  • Moderate stroke (NIHSS 8–15): Start DOAC at days 2–4
  • Severe stroke (NIHSS >15, large infarct): Start DOAC at days 5–7; consider repeat imaging before initiation
  • Hemorrhagic transformation: Petechial HT (HI-1, HI-2) does not preclude early anticoagulation; parenchymal hematoma (PH-1, PH-2) — delay until stable, individualize

Key point: The traditional approach of delaying anticoagulation 1–2 weeks is now largely obsolete. ELAN, OPTIMAS, and TIMING collectively support earlier initiation without increased bleeding risk.

Mechanical Heart Valves

Patients with mechanical prosthetic heart valves require lifelong anticoagulation. Warfarin is the ONLY option—DOACs are contraindicated and cause harm.

RE-ALIGN Trial (2013)

This trial tested dabigatran vs warfarin in patients with mechanical heart valves:

  • Stopped early for harm
  • Dabigatran: More thromboembolic events (5% vs 0%) and major bleeding (4% vs 2%)
  • Mechanism: Mechanical valves require consistent suppression of contact pathway activation—dabigatran’s pharmacokinetics inadequate

🚫 Mechanical Valves: Warfarin Only

Never use DOACs in mechanical heart valve patients. RE-ALIGN showed dabigatran caused excess thromboembolism and bleeding. Warfarin with INR 2.5–3.5 (higher for mitral position or older valves) remains mandatory.

Antiphospholipid Syndrome (APS)

Antiphospholipid syndrome causes arterial and venous thrombosis through antibody-mediated endothelial dysfunction and platelet activation. High-risk (“triple-positive”) patients have lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies.

TRAPS Trial (2018) + 2-Year Follow-up (2021)

Rivaroxaban vs warfarin in triple-positive APS:

  • Stopped early for excess arterial thrombosis in rivaroxaban arm
  • 2-year outcomes: Composite events 33.3% (rivaroxaban) vs 5.7% (warfarin), HR 6.9
  • Thrombotic events: HR 13.3 favoring warfarin

ASTRO-APS/TAPS Trial (2022)

Apixaban vs warfarin in thrombotic APS:

  • Stopped early—all strokes occurred in apixaban group (6/23 vs 0/25)
  • Demonstrates class effect: DOACs inadequate for APS

🚫 Antiphospholipid Syndrome: Warfarin Preferred

Do not use DOACs in APS, especially triple-positive patients. Both TRAPS (rivaroxaban) and ASTRO-APS (apixaban) were stopped for excess thrombosis with DOACs. Warfarin with INR 2–3 (or 3–4 for recurrent events) remains standard.

Cervical Artery Dissection

Cervical artery dissection (carotid or vertebral) causes stroke through artery-to-artery embolism from the intimal flap or vessel occlusion. The optimal antithrombotic strategy has been debated for decades.

CADISS Trial (2015)

250 patients randomized to antiplatelet vs anticoagulation within 7 days of dissection:

  • Stroke at 3 months: 2.5% in both groups (no difference)
  • Recurrent stroke was rare overall (low event rate limited power)
  • Recanalization rates similar between groups

TREAT-CAD (2021)

Aspirin vs vitamin K antagonist in cervical artery dissection:

  • Aspirin did not meet non-inferiority criteria
  • Trend toward more strokes with aspirin (3.3% vs 1.5%)
  • Subgroup analysis: Anticoagulation may benefit occlusive dissection (HR 0.40)

Practical Approach

  • Either antiplatelet or anticoagulation is acceptable (CADISS)
  • Consider anticoagulation for: occlusive dissection, recurrent events, extensive thrombus
  • Duration: Typically 3–6 months, then reassess with imaging
  • DOACs increasingly used (no RCT data, but observational studies suggest safety)

Cerebral Venous Thrombosis (CVT)

CVT requires anticoagulation to prevent thrombus propagation and facilitate recanalization. Historically, heparin followed by warfarin was standard. DOACs are now emerging as alternatives.

RE-SPECT CVT (2019)

Dabigatran 150mg BID vs warfarin for 24 weeks after initial parenteral anticoagulation:

  • Recurrent VTE: 0% in both arms
  • Major bleeding: 1.7% (dabigatran) vs 3.3% (warfarin)
  • Recanalization: 60% vs 67% (similar)
  • Functional outcome (mRS 0–1): 91.5% vs 91.4%

ACTION-CVT / DOAC-CVT Registries

Large observational studies confirm DOACs appear safe and effective in CVT, with similar or lower bleeding rates than warfarin.

Practical Approach

  • DOACs are reasonable alternatives to warfarin for CVT
  • Start with parenteral anticoagulation (heparin/LMWH) in acute phase
  • Transition to oral anticoagulation once stable
  • Duration: 3–12 months depending on provoked vs unprovoked and risk factors

LV Thrombus and Intracardiac Thrombus

Left ventricular thrombus typically forms after anterior MI with akinetic/dyskinetic segments, or in dilated cardiomyopathy. Anticoagulation prevents systemic embolization.

Current Evidence

  • Warfarin is traditional standard (INR 2–3 for 3–6 months)
  • DOACs: Observational data suggest similar efficacy; RCTs ongoing
  • Some studies suggest higher thrombus persistence with DOACs vs warfarin
  • Consider warfarin for large/mobile thrombi; DOACs may be acceptable for smaller thrombi

Detection

Cardiac CT angiography (CCTA) detects LV/LA thrombus in up to 17% of cryptogenic stroke patients—significantly more than TTE alone. Consider extended cardiac imaging in ESUS workup.

Patent Foramen Ovale (PFO)

PFO allows paradoxical embolism from venous thrombi. In cryptogenic stroke with high-risk PFO features (large shunt, atrial septal aneurysm), closure is preferred over medical therapy.

Key Trials

CLOSE (2017) — PFO closure reduced stroke from 14 events to 0 vs antiplatelets alone (HR 0.03) in patients with ASA or large shunt.

RESPECT (Extended, 2017) — PFO closure reduced recurrent stroke (HR 0.55 overall; HR 0.38 for cryptogenic stroke).

REDUCE (2017) — Closure reduced stroke from 5.4% to 1.4% (HR 0.23).

Hierarchy of Evidence

  1. PFO closure + antiplatelet — Most effective for high-risk features
  2. Anticoagulation — Reasonable if closure not feasible (CLOSE showed trend toward benefit)
  3. Antiplatelet alone — Least effective in high-risk PFO

Other Indications

Rheumatic Mitral Stenosis

Patients with rheumatic mitral valve disease and AF require warfarin. They were excluded from DOAC trials, so no data support DOAC use.

Cancer-Associated Stroke

Trousseau syndrome (cancer hypercoagulability) may cause stroke. LMWH or DOACs (edoxaban, rivaroxaban) are options depending on cancer type and bleeding risk.

Inherited Thrombophilias

Factor V Leiden, prothrombin mutation, protein C/S deficiency—anticoagulation indicated for venous events. Arterial stroke from thrombophilia is less common; treatment individualized.

🔹 Bottom Line: Anticoagulation Selection

  • Atrial fibrillation: DOACs preferred over warfarin (less ICH, similar/better efficacy)
  • Mechanical valves: Warfarin ONLY—DOACs cause harm (RE-ALIGN)
  • Antiphospholipid syndrome: Warfarin preferred—DOACs inferior (TRAPS, ASTRO-APS)
  • Cervical dissection: Antiplatelet or anticoagulation both acceptable (CADISS)
  • CVT: DOACs appear equivalent to warfarin (RE-SPECT CVT)
  • LV thrombus: Warfarin traditional; DOACs increasingly used
  • Timing post-stroke: Early DOAC (≤4 days) is safe in AF (ELAN, OPTIMAS)

Oral Anticoagulant Pharmacology Comparison

Property Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism Vitamin K epoxide reductase inhibitor (↓II, VII, IX, X) Direct thrombin (IIa) inhibitor Direct factor Xa inhibitor Direct factor Xa inhibitor Direct factor Xa inhibitor
Prodrug No Yes (dabigatran etexilate) No No No
Bioavailability ~100% 6–7% 80–100% (with food) 50% 62%
Half-life 36–42 hours 12–17 hours 5–9 hours (young); 11–13h (elderly) 8–15 hours 10–14 hours
Renal Elimination Minimal 80% 33% 27% 50%
CrCl Cutoff No specific cutoff Avoid if <30 (US); <15 (Europe) Avoid if <15 Caution if <25; avoid <15 Avoid if <15; reduce dose <50
Dosing (AF) Titrate to INR 2–3 150mg BID (110mg BID if age ≥80 or bleeding risk) 20mg daily with food (15mg if CrCl 15–50) 5mg BID (2.5mg if ≥2: age ≥80, wt ≤60kg, Cr ≥1.5) 60mg daily (30mg if CrCl 15–50, wt ≤60kg, or P-gp inhibitor)
Peak Effect 72–96 hours 1–3 hours 2–4 hours 3–4 hours 1–2 hours
Duration After Stopping 4–5 days 1–2 days (longer if renal impairment) 1–2 days 1–2 days 1–2 days
Drug Interactions Extensive (CYP2C9, 3A4, 1A2; vitamin K intake) P-gp inhibitors/inducers Strong CYP3A4 and P-gp inhibitors Strong CYP3A4 and P-gp inhibitors P-gp inhibitors
Food Effect Vitamin K affects INR None significant Take with food (↑absorption) None significant None significant
Monitoring INR (target 2–3) Not routine; dTT, ECT, or dilute thrombin time if needed Not routine; anti-Xa level if needed Not routine; anti-Xa level if needed Not routine; anti-Xa level if needed
Reversal Agent Vitamin K, FFP, PCC, rFVIIa Idarucizumab (Praxbind) Andexanet alfa (Andexxa); 4F-PCC Andexanet alfa (Andexxa); 4F-PCC Andexanet alfa; 4F-PCC
GI Side Effects Rare Dyspepsia common (10–15%) Uncommon Uncommon Uncommon
GI Bleeding Risk Moderate Higher than warfarin (150mg dose) Similar or higher than warfarin Lower than warfarin Lower than warfarin
ICH Risk vs Warfarin Reference ~60% reduction ~30% reduction ~50% reduction ~50% reduction
Hold Before Surgery 5 days (bridge if high risk) 1–2 days (2–4 if CrCl <50) 1–2 days (longer if renal impairment) 1–2 days 1–2 days
Dialyzable No Yes (~60% removed) No (highly protein-bound) No (highly protein-bound) No
Pregnancy Contraindicated (teratogenic) Contraindicated Contraindicated Contraindicated Contraindicated

References

  1. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med. 2009;361:1139–1151.
  2. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). N Engl J Med. 2011;365:883–891.
  3. Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365:981–992.
  4. Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48). N Engl J Med. 2013;369:2093–2104.
  5. Eikelboom JW, et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). N Engl J Med. 2013;369:1206–1214.
  6. Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood. 2018;132:1365–1371.
  7. Ordi-Ros J, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome (RAPS). Ann Intern Med. 2019;171:685–694.
  8. Markus HS, et al. Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection (CADISS). Lancet Neurol. 2015;14:361–367.
  9. Ferro JM, et al. Dabigatran etexilate versus dose-adjusted warfarin in cerebral venous thrombosis (RE-SPECT CVT). Lancet Neurol. 2019;18:1147–1156.
  10. Paciaroni M, et al. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation (ELAN). N Engl J Med. 2023;389:1167–1179.
  11. OPTIMAS Investigators. Timing of anticoagulation after acute ischaemic stroke in atrial fibrillation (OPTIMAS). Lancet. 2024;404:1573–1585.
  12. Mas JL, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke (CLOSE). N Engl J Med. 2017;377:1011–1021.
  13. Saver JL, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke (RESPECT Extended). N Engl J Med. 2017;377:1022–1032.